Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.50    0.00 (0.00%)
Bid:
66.00
Ask:
67.00
Spread: 1.00 (1.515%)
Market Cap: £80.67m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

UltraDEX update

30 Apr 2018 07:00

RNS Number : 4552M
Venture Life Group PLC
30 April 2018
 

Venture Life Group plc

("Venture Life" or "the Company")

 

UltraDEX update

 

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the self-care market announces an update on the UltraDEX brand. The Company has extended its agreement with key French distributor La Brosse et Dupont SAS ("La Brosse") to include the UltraDEX Sensitive toothpaste. The launch will take place in H2 2018 and follows the successful launch of the original UltraDEX range in Q1 2018 in France.

 

Founded in 1932, La Brosse is a former subsidiary of LVMH Moet Hennessy Louis Vuitton S.E. It serves customers through large and medium commercial outlets throughout France, including Leclerc and Carrefour, and has market leading products within the oral healthcare space. Le Brosse launched the original UltraDEX range into the French market during March 2018 and is building up a presence in the grocery multiples.

 

UltraDEX was also partnered in Italy and the Nordics in 2017, and after delivery of product in Q4 2017, these partners have also launched UltraDEX into their respective markets during H1 2018. Both partners are building a presence for the mouthwash, toothpaste and spray products in pharmacies and dentists, and early indications are positive for the sell through.

 

Separately, the Company announces the launch of the new UltraDEX 'One GoÔ' range in all 797 of the Superdrug stores in the UK from June 2018. UltraDEX 'One Go' is another new innovative line extension from the Company, providing single use sachets of the UltraDEX mouthwash.

 

Jerry Randall, CEO of Venture Life commented: "The extension of this agreement with La Brosse is a real testament to the continued international success of UltraDEX, particularly at such an early stage in their launch of the UltraDEX range in France. I am delighted with the continued commercial development of the UltraDEX brand both in the UK and internationally, and we look forward updating the market further throughout the rest of the year.

 

"It's also great news that our new product, UltraDEX 'One Go', has been so quickly adopted by one of the leading pharmacy chains, Superdrug, demonstrating our ability to rapidly develop and launch innovative new products into the consumer self-care channel, and we are hopeful to extend its presence further. Innovation is key to the growth of consumer brands, and Venture Life has the experience and capabilities to develop and commercialise such new products."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

 

 

Enquiries

 

Venture Life Group PLC

+44 (0) 1344 578 004

Jerry Randall, Chief Executive Officer

Adrian Crockett, Chief Financial Officer

 

Northland Capital Partners Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 3861 6625

Matthew Johnson/Edward Hutton (Corporate Finance)

Bob Pountney (Corporate Broking)

Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

Andy Thacker

Walbrook PR

venturelife@walbrookpr.com or +44 (0) 20 7933 8780

Anna Dunphy/Paul McManus

+44 (0) 7876 741 001 / +44 (0) 7980 541 893

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDLLFLESDIDFIT
Date   Source Headline
9th Dec 20257:00 amRNSSale of Non-Core Products
8th Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20254:30 pmRNSTotal Voting Rights
1st Dec 20257:00 amRNSTransaction in Own Shares
28th Nov 20257:00 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
3rd Oct 20254:40 pmRNSDirector/PDMR Shareholding
30th Sep 20257:01 amRNSShare Buyback Programme
30th Sep 20257:00 amRNSInterim Results
29th Sep 202512:19 pmRNSInvestor Presentation via Investor Meet Company
24th Sep 20252:38 pmRNSChange of Accounting Reference Date
8th Sep 20257:00 amRNSDirectorate Change
19th Aug 20252:04 pmRNSHolding(s) in Company
5th Aug 20253:43 pmRNSResult of General Meeting
25th Jul 20257:05 amRNSGrant of Share Options
25th Jul 20257:00 amRNSCompletion of Divestment & Trading Update
7th Jul 20254:21 pmRNSDirector/PDMR Shareholding
3rd Jul 20257:00 amRNSDirector Dealings
2nd Jul 20257:00 amRNSNotice of General Meeting & Investor Presentation
1st Jul 20254:08 pmRNSHolding(s) in Company
30th Jun 20253:15 pmRNSResult of AGM
30th Jun 20253:13 pmRNSFinal Results for year ended 31 December 2024
5th Jun 20252:19 pmRNSNotice of Annual General Meeting
19th May 20257:01 amRNSDirector Dealings
19th May 20257:00 amRNSBoard Update
12th May 20258:49 amRNSReplacement: Cash sale of CDMO operations
12th May 20257:00 amRNSCash sale of CDMO operations
28th Apr 202510:50 amRNSHolding(s) in Company
8th Apr 20254:53 pmRNSHolding(s) in Company
20th Feb 20251:14 pmRNSHolding(s) in Company
18th Feb 202510:02 amRNSHolding(s) in Company
4th Feb 20257:01 amRNSBoard Changes
4th Feb 20257:00 amRNSTrading Statement
21st Jan 20258:15 amRNSExercise of Share Options & Total Voting Rights
20th Jan 202511:49 amRNSHolding(s) in Company
19th Dec 202411:48 amRNSHolding(s) in Company
4th Nov 20243:44 pmRNSHolding(s) in Company
30th Oct 202412:01 pmRNSDirector/PDMR Shareholding
30th Oct 202410:58 amRNSDirector/PDMR Shareholding
30th Oct 20247:00 amRNSAcquisition of Health & Her Limited
1st Oct 202412:47 pmRNSHolding(s) in Company
30th Sep 20247:00 amRNSInterim Results
26th Sep 20247:00 amRNSInvestor Presentation via Investor Meet Company
2nd Sep 202410:41 amRNSDirector/PDMR Shareholding
2nd Sep 202410:40 amRNSReplacement - Exercise of Options & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.